Latest Biotechnology News

Page 67 of 80
Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.
Ada Torres
Ada Torres
5 May 2025
Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.
Ada Torres
Ada Torres
5 May 2025
Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.
Ada Torres
Ada Torres
2 May 2025
Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.
Ada Torres
Ada Torres
2 May 2025
AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.
Ada Torres
Ada Torres
1 May 2025
Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.
Ada Torres
Ada Torres
1 May 2025
Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.
Ada Torres
Ada Torres
1 May 2025
AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy by executing three CAR-T term sheets and completing technical due diligence, while implementing cost-cutting measures and seeking new capital amid a tough financing environment.
Ada Torres
Ada Torres
1 May 2025
Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.
Ada Torres
Ada Torres
30 Apr 2025
Anatara Lifesciences reports mixed results from its Phase II GaRP-IBS trial, missing the primary efficacy target but showing significant improvements in anxiety and patient-reported relief, while advancing its anti-obesity pre-clinical program.
Ada Torres
Ada Torres
30 Apr 2025
Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.
Ada Torres
Ada Torres
30 Apr 2025
Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.
Ada Torres
Ada Torres
30 Apr 2025